Evidence map›Paper›PMID 38680224›Full record

Observational studyIranian journal of medical sciences2024

High Post-Infection Protection after COVID-19 among Healthcare Workers: A Population-Level Observational Study.

Sepehr Shahriarirad, Naeimehossadat Asmarian, Reza Shahriarirad, Mohsen Moghadami, Mehrdad Askarian, Leila Hashemizadeh Fard Haghighi, Parisa Javadi, Golnar Sabetian

Abstract readObservational Study
In one paragraph

Observational study in Iranian journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sepehr ShahriariradThoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Naeimehossadat AsmarianAnesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Reza ShahriariradThoracic and Vascular Surgery Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohsen MoghadamiClinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehrdad AskarianDepartment of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila Hashemizadeh Fard HaghighiVice Chancellor for Health Affairs Center of Disease Control (CDC), Shiraz University of Medical Sciences, Shiraz, Iran.
Parisa JavadiDepartment of Anesthesiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Golnar SabetianTrauma Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Even though a few years have passed since the coronavirus disease 2019 (COVID-19) outbreak, information regarding certain aspects of the disease, such as post-infection immunity, is still quite limited. This study aimed to evaluate post-infection protection and COVID-19 features among healthcare workers (HCWs), during three successive surges, as well as the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection, reactivation, re-positivity, and severity. Methods: This cross-sectional population-level observational study was conducted from 20 April 2020 to 18 February 2021. The study population included all HCWs in public or private hospitals in Fars Province, Southern Iran. The infection rate was computed as the number of individuals with positive polymerase chain reaction (PCR) tests divided by the total number of person-days at risk. The re-infection was evaluated after 90 days. Results: A total of 30,546 PCR tests were performed among HCWs, of which 13,749 (61.94% of total HCWs) were positive. Considering the applied 90-day threshold, there were 44 (31.2%) cases of reactivation and relapse, and 97 (68.8% of infected and 1.81% of total HCWs) cases of reinfection among 141 (2.64%) diagnosed cases who experienced a second episode of COVID-19. There was no significant difference in symptoms (P=0.65) or the necessity for ICU admission (P=0.25). The estimated protection against repeated infection after a previous SARS-CoV-2 infection was 94.8% (95% CI=93.6-95.7). Conclusion: SARS-CoV-2 re-positivity, relapse, and reinfection were rare in the HCW population. After the first episode of infection, an estimated 94.8% protection against recurring infections was achieved. A preprint version of this manuscript is available at DOI:10.21203/rs.3.rs-772662/v1 (https://www.researchsquare.com/article/rs-772662/v1).

Indexed as

COVID-19Health PersonnelAdultCross-Sectional StudiesFemaleHumansIranMaleMiddle AgedReinfectionSARS-CoV-2COVID-19Healthcare workerPolymerase chain reactionReinfectionRelapse

Identifiers

PMID38680224
PMCPMC11053253

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.